Be positive: optimizing pramlintide from microcanonical analysis of amylin isoforms

Area of Science:

• Biochemistry
• Computational Biology
• Endocrinology

Background:

• Amylin (human islet amyloid polypeptide, hIAPP) is co-secreted with insulin and its amyloid fibril deposition is linked to Type II diabetes (T2D) progression and islet graft failure.
• Mammalian amylin isoforms (e.g., rat and porcine) possess mutations that inhibit aggregation, inspiring drug development like pramlintide, a modified hIAPP.
• Current adjunct therapies for T2D, such as pramlintide, face formulation challenges due to poor solubility, hindering co-administration with insulin.

Purpose of the Study:

• To introduce a computational methodology for assessing protein thermostability and guiding drug design for T2D adjunct therapies.
• To systematically evaluate wild-type amylin isoforms using microcanonical thermostatistics and multicanonical (MUCA) simulations.
• To identify optimal single-point mutations for enhancing pramlintide's efficacy by improving solubility and aggregation inhibition.

Main Methods:

• Microcanonical thermostatistics analysis of multicanonical (MUCA) simulations.
• Systematic assessment of wild-type amylin isoform thermostability.
• Identification of single-point mutations for drug optimization.

Main Results:

• The study identified specific single-point mutations within wild-type amylin isoforms that can optimize pramlintide.
• Aggregation inhibition and increased solubility were observed in pramlintide through an S20R substitution, characteristic of porcine amylin (pIAPP).
• Thermostatistical analysis provided insights into protein behavior relevant to drug design.

Conclusions:

• A consistent thermostatistical methodology can aid in the rational design of improved adjunct therapies for T2D.
• The S20R substitution offers a promising strategy for enhancing pramlintide's properties for T2D treatment.
• Computational simulations provide valuable thermodynamic insights for developing more effective diabetes medications.